234 related articles for article (PubMed ID: 28042702)
1. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
[No Abstract] [Full Text] [Related]
2. Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model.
Teixeira C; Costelha S; Martins HS; Teixeira A; Saraiva MJ
Amyloid; 2017 Mar; 24(sup1):80. PubMed ID: 28434372
[No Abstract] [Full Text] [Related]
3. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
4. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M
Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374
[No Abstract] [Full Text] [Related]
6. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C
Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637
[No Abstract] [Full Text] [Related]
7. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
9. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser).
Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM
Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724
[No Abstract] [Full Text] [Related]
10. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen.
Dasgupta NR; Benson MD
Amyloid; 2019; 26(sup1):20-21. PubMed ID: 31343363
[No Abstract] [Full Text] [Related]
11. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
Sattianayagam PT; Hahn AF; Whelan CJ; Gibbs SD; Pinney JH; Stangou AJ; Rowczenio D; Pflugfelder PW; Fox Z; Lachmann HJ; Wechalekar AD; Hawkins PN; Gillmore JD
Eur Heart J; 2012 May; 33(9):1120-7. PubMed ID: 21992998
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
13. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
14. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study.
Obici L; Cortese A; Lozza A; Lucchetti J; Gobbi M; Palladini G; Perlini S; Saraiva MJ; Merlini G
Amyloid; 2012 Jun; 19 Suppl 1():34-6. PubMed ID: 22551192
[TBL] [Abstract][Full Text] [Related]
15. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.
Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS
Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin amyloidosis: a little history of hereditary amyloidosis.
Benson MD
Amyloid; 2017 Mar; 24(sup1):76-77. PubMed ID: 28434305
[No Abstract] [Full Text] [Related]
18. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.
Wixner J; Westermark P; Ihse E; Pilebro B; Lundgren HE; Anan I
Amyloid; 2019; 26(sup1):39-40. PubMed ID: 31343354
[No Abstract] [Full Text] [Related]
19. Tafamidis Treatment Decreases
Yu AL; Chen YC; Tsai CH; Chao CC; Su MY; Juang JJ; Lee MJ; Hsieh ST; Cheng MF; Lin YH
JACC Cardiovasc Imaging; 2023 Jun; 16(6):866-867. PubMed ID: 36881423
[No Abstract] [Full Text] [Related]
20. Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis.
Karlstedt E; Jimenez-Zepeda V; Howlett JG; White JA; Fine NM
J Card Fail; 2019 Mar; 25(3):147-153. PubMed ID: 30660664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
